Ilaria Cattarossi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10193588/publications.pdf

Version: 2024-02-01

20 papers	720 citations	623699 14 h-index	888047 17 g-index
20 all docs	20 docs citations	20 times ranked	1092 citing authors

#	Article	IF	Citations
1	COVIDâ€19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients. Hematological Oncology, 2021, 39, 712-714.	1.7	17
2	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. Blood, 2020, 135, 1244-1254.	1.4	33
3	Clinical Impact of Clonal and Subclonal TP53 Mutations and Deletions in Chronic Lymphocytic Leukemia: An Italian Multicenter Experience. Blood, 2019, 134, 480-480.	1.4	12
4	Intraclonal Diversification Occurs in Chronic Lymphocytic Leukemia Expressing B Cell Receptors Belonging to the IGHV4 Gene Family. Blood, 2018, 132, 944-944.	1.4	0
5	Clinical Impact of Clonal and Subclonal TP53 Mutations in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 945-945.	1.4	0
6	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia, 2016, 30, 2011-2018.	7.2	41
7	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. Immunology Letters, 2011, 134, 137-144.	2.5	17
8	Expression of Mutated IGHV3-23 Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44
9	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. British Journal of Haematology, 2009, 144, 492-506.	2.5	106
10	Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma. Journal of Immunotherapy, 2002, 25, 16-26.	2.4	111
11	Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunology, Immunotherapy, 2002, 51, 9-14.	4.2	38
12	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-?. International Journal of Cancer, 2001, 91, 500-507.	5.1	10
13	Unbalanced expression of HLAâ€A and â€B antigens: A specific feature of cutaneous melanoma and other nonâ€hemopoietic malignancies reverted by IFNâ€Î³. International Journal of Cancer, 2001, 91, 500-507.	5.1	1
14	Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. Breast Cancer Research and Treatment, 1999, 58, 19-23.	2.5	19
15	Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2??-deoxycytidine (5-AZA-CdR). Journal of Immunotherapy, 1999, 22, 16-24.	2.4	119
16	Transduction of protectin (CD59) enhances the resistance of human melanomas to homologous CDC. Molecular Immunology, 1998, 35, 412.	2.2	0
17	Tumour-derived interleukin 1Î± (IL-1Î±) up-regulates the release of soluble intercellular adhesion molecule-1 (sICAM-1) by endothelial cells. British Journal of Cancer, 1997, 76, 1255-1261.	6.4	25
18	Melanoma cells constitutively release an anchor-positive soluble form of protectin (sCD59) that retains functional activities in homologous complement-mediated cytotoxicity.. Journal of Clinical Investigation, 1997, 100, 1248-1255.	8.2	33

#	Article	IF	Citations
19	Expression and structural features of endoglin (CD105), a transforming growth factor Î²1 and Î²3 binding protein, in human melanoma. British Journal of Cancer, 1996, 74, 1586-1591.	6.4	58
20	Expression of protectin (CD59) in human melanoma and its functional role in cell- and complement-mediated cytotoxicity. International Journal of Cancer, 1995, 61, 548-556.	5.1	36